KARRY VIOLETTE

H.R. 879/S. 1640, the Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 1, the One Big Beautiful Bill Act; H.R. 3164/S. 2426, the Ensuring Community Access to Pharmacist Services Act; Draft legislation to amend title XVIII of the Social Security Act to modify the conversion factor updates applicable to physicians' services under the Medicare program; Implementation of Centers for Medicare & Medicaid Services. (2025). Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program. Federal Register, 88, 90 FR 49266-50481; H.R. 6160, the Strengthening Medicare for Patients and Providers Act; H.R. 8163, the Provider Reimbursement Stability Act; H.R. 7520, the Efficiency Adjustment Delay Act; H.R. 8622, the Medicare Physician Data-driven Performance Payment System Act of 2026 H.R.9693, Patients First Act of 2026 H.R.4331, Access to Claims Data Act Proposed CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program

Revised military shaving waiver policies; Sunscreen access for servicemembers

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act.

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. H.R. 5213, the Reducing Medically Unnecessary Delays in Care Act of 2023. H.R. 6445/S.2377, the Medicare Audiology Access Improvement Act of 2023. H.R. 6487/S.3805, the No Fees for EFTs Act. H.R. 6545, the Physician Fee Schedule Update and Improvements Act. H.R. 6683, the Preserving Seniors' Access to Physicians Act of 2023; Draft legislation, To amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-Driven Performance Payment System under the Medicare physician fee schedule, and for other purposes; H.R. 8702/S. 4532, the Improving Seniors Timely Access to Care Act; S. 3503/H.R. 5013, Value in Health Care Act; S. 4935, Physician Fee Stability Act; S. 2477/H.R. 1770, Equitable Community Access to Pharmacist Services Act; H.R. 10073, the Medicare Patient Access and Practice Stabilization Act of 2024; H.R. 10545, the American Relief Act, 2025

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives. H.R.7153/S.3679, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act. S.Res.567/H.Res.1089, a resolution recognizing the seriousness of widespread health care worker burnout in the United States and the need to strengthen health workforce well-being, and expressing support for the designation of March 18, 2024, as the inaugural "Health Workforce Well-Being Day of Awareness".; H.R. 2819, Good Samaritan Health Professionals Act; S. 4349, Electronic Prior Authorization for Prescription Drugs Act

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Oppose H.R.936/S.1937, Tanning Tax Repeal Act

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. H.R. 5213, the Reducing Medically Unnecessary Delays in Care Act of 2023. H.R. 6445/S.2377, the Medicare Audiology Access Improvement Act of 2023. H.R. 6487/S.3805, the No Fees for EFTs Act. H.R. 6545, the Physician Fee Schedule Update and Improvements Act. H.R. 6683, the Preserving Seniors' Access to Physicians Act of 2023; Draft legislation, To amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-Driven Performance Payment System under the Medicare physician fee schedule, and for other purposes; H.R. 8702/S. 4532, the Improving Seniors Timely Access to Care Act; S. 3503/H.R. 5013, Value in Health Care Act; S. 4935, Physician Fee Stability Act; S. 2477/H.R. 1770, Equitable Community Access to Pharmacist Services Act

Oppose H.R.936/S.1937, Tanning Tax Repeal Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill (H.R.4821/S.2605). Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365/S.2587). Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127) H.R.4366, the Consolidated Appropriations Act, 2024

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act.

Oppose H.R.936/S.1937, Tanning Tax Repeal Act

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill (H.R.4821/S.2605). Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365/S.2587). Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127) H.R.4366, the Consolidated Appropriations Act, 2024

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act.

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. H.R. 5213, the Reducing Medically Unnecessary Delays in Care Act of 2023. H.R. 6445/S.2377, the Medicare Audiology Access Improvement Act of 2023. H.R. 6487/S.3805, the No Fees for EFTs Act. H.R. 6545, the Physician Fee Schedule Update and Improvements Act. H.R. 6683, the Preserving Seniors' Access to Physicians Act of 2023; Draft legislation, To amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-Driven Performance Payment System under the Medicare physician fee schedule, and for other purposes; H.R. 8702/S. 4532, the Improving Seniors Timely Access to Care Act

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. H.R. 5213, the Reducing Medically Unnecessary Delays in Care Act of 2023. H.R. 6445/S.2377, the Medicare Audiology Access Improvement Act of 2023. H.R. 6487/S.3805, the No Fees for EFTs Act. H.R. 6545, the Physician Fee Schedule Update and Improvements Act. H.R. 6683, the Preserving Seniors' Access to Physicians Act of 2023;

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill (H.R.4281/S.2605). Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365/S.2587). Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127) H.R.4366, the Consolidated Appropriations Act, 2024

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill (H.R.4281/S.2605). Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365/S.2587). Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127)

Oppose H.R.936/S.1937, Tanning Tax Repeal Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act.

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. H.R. 5213, the Reducing Medically Unnecessary Delays in Care Act of 2023. H.R. 6445/S.2377, the Medicare Audiology Access Improvement Act of 2023. H.R. 6487, the No Fees for EFTs Act. H.R. 6545, the Physician Fee Schedule Update and Improvements Act. H.R. 6683, the Preserving Seniors' Access to Physicians Act of 2023;

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act.

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill (H.R.4281/S.2605). Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365/S.2587). Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127)

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill . Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635).

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365) Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127)

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Support S. 127, Pharmacy Benefit Manager Transparency Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S.1302/H.R. 2389) Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries.

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389). Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries.

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365) Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127)

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes. Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021 Support H.R. 8437, the Improving Seniors Timely Access to Care Act of 2022 Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes. Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Support H.R. 7995, GOLD CARD Act of 2022 Advocate to provide relief from the 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2 (H.R. 2617, Consolidated Appropriations Act). Support H.R. 8800, Supporting Medicare Providers Act of 2022 Advocate against H.R 6708, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Oppose H.R. 8812, the Improving Care & Access to Nurses Act (I CAN Act)

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Support the Eliminating Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079). Oppose the Tanning Tax Repeal Act (H.R. 5642) Support the Indian Health Service Health Professions Tax Fairness Act (S. 2874)

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2023 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 8295, H.R. 2617)). Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Advocate for Defense Health Research Programs (CDMRP) in the FY23 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 8236, H.R. 2617).

Support for the Good Samaritan Health Professionals Act (H.R. 5239/ S. 2941), which would provide medical professionals with a limited, but consistent, level of legal protection while volunteering during federally-declared disasters.

Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences.

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. (H.R. 6000) Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package. Support the Knowing the Efficiency and Efficacy of Permanent (KEEP) Telehealth Options Act (H.R. 1677/S. 620). Support H.R.8437, the Improving Seniors Timely Access to Care Act of 2022 Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021 Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 8800, the Supporting Medicare Providers Act of 2022 Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Support H.R. 7995, GOLD CARD Act of 2022

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2023 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 8295). Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Advocate for Defense Health Research Programs (CDMRP) in the FY23 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 8236).

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2023 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 8295). Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2023 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 8295). Advocate for funding for the Pediatric Subspecialty Loan Repayment Program (PSLRP). Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Advocate for increased funding for the Indian Health Services via the FY 2023 Interior-Environment Appropriations bill (H.R. 8262). Advocate for Defense Health Research Programs (CDMRP) in the FY23 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 8236).

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. (S. 610) Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021 Support H.R. 8437, the Improving Seniors Timely Access to Care Act of 2022 Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes. Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Support H.R. 7995, GOLD CARD Act of 2022 Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 8800, Supporting Medicare Providers Act of 2022 Advocate against H.R 6708, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program.

Support for liability protections for physicians and health care facilities during the COVID Public Health Emergency (PHE). Support the Coronavirus Provider Protection Act (H.R. 3021). Support for the Good Samaritan Health Professionals Act (H.R. 5239/ S. 2941), which would provide medical professionals with a limited, but consistent, level of legal protection while volunteering during federally-declared disasters.